| 摘要: |
| ［摘要］ 目前，艾滋病病毒（HIV）疫苗的研究进展缓慢，暴露前预防（PrEP）HIV感染在高危人群中的效果已被多项临床试验研究证实，世界卫生组织（WHO）和美国疾病预防控制中心（CDC）均公布了PrEP作为一项新的HIV干预措施用药指南，旨在降低高危人群HIV新发感染率。而PrEP作为一项公共政策推广，需要了解其成本效益情况。该文对PrEP的卫生经济学评价情况作一综述。 |
| 关键词: 暴露前预防 艾滋病病毒 卫生经济学评价 |
| DOI：10.3969/j.issn.1674-3806.2017.07.35 |
| 分类号:R 1-9 |
| 基金项目:广西艾滋病防治研究重点实验室开放课题基金项目（编号:gklapt201604）;广西卫计委科研课题（编号:Z2014625，Z2016448）;广西壮族自治区疾病预防控制中心科技创新课题（编号:GXCDCCK-011） |
|
| Progress in the study of health economic evaluation on pre-exposure prophylaxis for HIV prevention |
|
WEI Suo-su, WU Teng-yan, TAN Yi
|
|
Progress in the study of health economic evaluation on pre-exposure prophylaxis for HIV prevention
|
| Abstract: |
| ［Abstract］ At present, the research progress of vaccine for human immunodeficiency virus(HIV） prevention has developed slowly. Pre-exposure prophylaxis(PrEP) has been proved by a number of clinical trials to be effective for prevention of HIV infection in high-risk populations. World Health Organization(WHO) and the Centers for Disease Control and Prevention of USA announced a clinical practice guideline that PrEP was taken as a new HIV intervention measure to the high-risk populations to reduce the rate of new HIV infections. Because PrEP becomes a public policy that needs to be extended, its cost- effectiveness must be known. The health economic evaluation of PrEP is reviewed in this paper. |
| Key words: Pre-exposure prophylaxis(PrEP) Human immunodeficiency virus(HIV） Health economics evaluation |
